Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Inclusion criteria

Inclusion criteria

• Male or female patient ≥ 50 yrs. of age.
• Active subfoveal or parafoveal CNV secondary to neovascular AMD.
• Willing and able to sign informed consent form and comply with visit and study procedures per protocol.

Exclusion criteria

• Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the standardized treatment);
• Presence of active intraocular or periocular inflammation or infection;
• History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine;
• Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study;
• Diabetic patients have any of the following conditions:HbA1c>7.5% when screening;